市場調査レポート
商品コード
1467891
消化性潰瘍治療薬市場:製品タイプ、潰瘍タイプ、流通チャネル、地域別、2024~2032年Peptic Ulcer Drugs Market by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker, Antacids, H2-Antagonists, Antibiotics, Ulcer protective), Ulcer Type, Distribution Channel, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
消化性潰瘍治療薬市場:製品タイプ、潰瘍タイプ、流通チャネル、地域別、2024~2032年 |
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2~3営業日
|
消化性潰瘍治療薬の世界市場規模は2023年に48億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに61億米ドルに達し、2024~2032年の間に2.65%の成長率(CAGR)を示すと予測しています。消化性潰瘍の有病率の増加、特に高齢者人口の増加、侵襲的な手術よりも様々な薬剤療法に対する消費者の傾向の変化は、市場を牽引する主要要因の一つです。
消化性潰瘍(十二指腸潰瘍)は、胃、小腸、食道下部の粘膜に徐々に発生し、欠陥を誘発する開放性の痛みです。消化性潰瘍は通常、炎症、放射線療法、アスピリンの頻繁な内服や注射、抗炎症剤投与などが原因で起こる。消化性潰瘍を放置すると、中・上半身の激痛、体重減少、内出血、大出血などを引き起こし、入院が必要になることもあります。現在、プロトンポンプ阻害薬(PPI)、H2拮抗薬、抗生物質、カリウムイオン競合型アシッドブロッカー(P-CAB)、制酸剤、潰瘍保護剤など、さまざまな種類の薬剤で治療することができます。これらの薬剤は、体の痛みを軽減し、治癒までの時間を長くし、酸の分泌を最小限に抑え、細菌感染に対する抵抗力を提供し、消化液から胃を保護します。その結果、消化性潰瘍治療薬は、胃炎、胃食道逆流症(GERD)、十二指腸潰瘍の治療に医療従事者によって広く利用されています。
消化性潰瘍の有病率が特に高齢者人口の間で増加していることが、市場の成長を促進する主要要因の1つとなっています。さらに、不健康な生活習慣や胃がんの増加により、消化性潰瘍を患う人の数が増加しています。これに加えて、侵襲的な手術よりも様々な消化性潰瘍治療薬に消費者の関心が移っていることも、市場成長に寄与しています。これに伴い、外科手術に比べ、ステロイド系抗炎症薬は低侵襲で価格も手ごろであり、出血量を減らしながら回復を早めることができます。さらに、消化性潰瘍治療薬の承認が進んでいることや、薬の製剤化のために政府が製薬会社に投資していることも、市場の成長を支えています。さらに、合併症を克服するための新薬開発のための継続的な臨床試験の実施や、市場における現行薬の効果の低さも影響しています。さらに、費用対効果の高い消化性潰瘍治療薬の利点に関する消費者の意識の高まりと、複数の流通チャネルで容易に入手できることが、市場の成長を後押ししています。また、診断と法医療的操作を行うための人工知能(AI)ベースの病理試験技術の登場も、市場の成長を後押ししています。製品の有効性を高めるための広範な研究開発(R&D)活動や、消化性潰瘍治療薬用の一般用医薬品(OTC)開発への投資の増加など、その他の要因も市場成長にプラスの影響を与えています。
The global peptic ulcer drugs market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 2.65% during 2024-2032. The increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various medications over invasive surgeries represent some of the key factors driving the market.
Peptic ulcers, or duodenal ulcers, are open sore that gradually develops and triggers defects in the lining of the stomach, small intestine, and lower esophagus. They are usually caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. If peptic ulcers are left untreated, they might initiate severe pain in the mid- or upper-body parts, weight loss, internal bleeding, and severe blood loss, which require hospitalization. Currently, they can be treated with various drug types, including proton pump inhibitors (PPI), H2 antagonists, antibiotics, potassium-competitive acid blockers (P-CAB), antacids, and ulcer protectives. These medications reduce body aches, provide more time to heal, minimize acid secretion, offer resistance against bacterial infections, and protect the stomach from digestive juices. As a result, peptic ulcer drugs are extensively utilized by healthcare practitioners for the treatment of gastritis, gastroesophageal reflux disease (GERD), and duodenal ulcers.
The increasing prevalence of peptic ulcers, especially amongst the geriatric population, represents one of the key factors driving the market growth. Moreover, unhealthy lifestyle habits and rising instances of stomach cancer, is resulting in the growing number of individuals suffering from peptic ulcers. This, along with the shifting consumer inclination towards various peptic ulcer-curing drugs over invasive surgeries, which, in turn, is contributing to the market growth. In line with this, as compared to surgical procedures, several steroidal anti-inflammatory medications are minimally invasive, more affordable, and enable faster recovery while ensuring reduced blood loss. Additionally, the ongoing approvals of peptic ulcer drugs and several government investments in pharmaceutical companies for the formulation of medications are supporting the market growth. This is further influenced by the continuous conduction of clinical trials for new drug formation to overcome complications and the ineffectiveness of present drugs in the market. Moreover, the increasing consumer awareness regarding the benefits of cost-effective peptic ulcer drugs and their easy availability across multiple distribution channels is favoring the market growth. The advent of artificial intelligence (AI)-based pathology testing technology to perform diagnostic and forensic operations is also propelling the market growth. Other factors, such as extensive research and development (R&D) activities to enhance product efficacy and the increasing investments in the development of the over the counter (OTC) medications for treating peptic ulcers, are positively impacting the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global peptic ulcer drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product type, ulcer type, and distribution channel.
Proton Pump Inhibitors
Potassium-Competitive Acid Blocker (P-CAB)
Antacids
H2-Antagonists
Antibiotics
Ulcer protective
The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the product type. This includes proton pump inhibitors, potassium-competitive acid blocker (P-CAB), antacids, H2-antagonists, antibiotics, and ulcer protective. According to the report, antibiotics represented the largest segment.
Gastric Ulcer
Duodenal Ulcer
Others
A detailed breakup and analysis of the peptic ulcer drugs market based on the ulcer type has also been provided in the report. This includes gastric ulcer, duodenal ulcer, and others. According to the report, duodenal ulcer accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for peptic ulcer drugs. Some of the factors driving the North America peptic ulcer drugs market included the increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various peptic ulcer curing drugs over invasive surgeries and the fueling need for over-the-counter (OTC) medications in the healthcare sector.
The report has also provided a comprehensive analysis of the competitive landscape in the global peptic ulcer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novitium Pharma LLC, Pfizer Inc., PharmaKing Co. Ltd., RedHill Biopharma Ltd, Viatris Inc., Yuhan Corporation, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.